10.31
0.68%
0.07
アフターアワーズ:
10.27
-0.04
-0.39%
前日終値:
$10.24
開ける:
$10.08
24時間の取引高:
2.43M
Relative Volume:
2.80
時価総額:
$597.46M
収益:
-
当期純損益:
$-117.81M
株価収益率:
16.11
EPS:
0.64
ネットキャッシュフロー:
$74.30M
1週間 パフォーマンス:
+35.12%
1か月 パフォーマンス:
+70.98%
6か月 パフォーマンス:
+160.68%
1年 パフォーマンス:
+244.82%
Omeros Corporation Stock (OMER) Company Profile
名前
Omeros Corporation
セクター
電話
206-676-5000
住所
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
10.31 | 597.46M | 0 | -117.81M | 74.30M | -1.88 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
2022-12-08 | ダウングレード | UBS | Buy → Neutral |
2022-11-08 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-06-08 | ダウングレード | BofA Securities | Buy → Neutral |
2021-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
2021-10-01 | ダウングレード | Maxim Group | Buy → Hold |
2021-10-01 | ダウングレード | Wedbush | Neutral → Underperform |
2021-09-27 | 開始されました | JP Morgan | Neutral |
2021-02-01 | 開始されました | UBS | Buy |
2020-10-20 | 開始されました | BofA Securities | Buy |
2020-08-21 | 繰り返されました | H.C. Wainwright | Buy |
2020-08-14 | 繰り返されました | Maxim Group | Buy |
2019-05-06 | 開始されました | Cantor Fitzgerald | Overweight |
2018-07-12 | 開始されました | Seaport Global Securities | Buy |
2018-03-23 | ダウングレード | Wedbush | Outperform → Neutral |
2018-03-05 | ダウングレード | Needham | Buy → Hold |
2017-11-08 | 開始されました | H.C. Wainwright | Buy |
2017-05-11 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
2017-03-17 | 繰り返されました | Maxim Group | Buy |
2017-03-17 | 繰り返されました | Needham | Buy |
2016-11-16 | 繰り返されました | Wedbush | Outperform |
2016-11-10 | 繰り返されました | Needham | Buy |
2016-08-10 | 繰り返されました | Maxim Group | Buy |
2016-06-03 | 開始されました | Cantor Fitzgerald | Buy |
2016-03-02 | 繰り返されました | Needham | Buy |
2016-02-29 | 繰り返されました | Wedbush | Outperform |
2015-11-11 | 繰り返されました | Needham | Buy |
2015-08-18 | 繰り返されました | WBB Securities | Strong Buy |
2015-08-10 | 開始されました | ROTH Capital | Buy |
すべてを表示
Omeros Corporation (OMER) 最新ニュース
Wellington Management Group LLP Invests $305,000 in Omeros Co. (NASDAQ:OMER) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros Corporation Announces Positive Results for Narsoplimab in Treating Thrombotic MicroangiopathyOn December 19, 2024, Omeros Corporation (NASDAQ: OMER) revealed the outcomes of a primary statistical analysis involving narsoplimab, the comp - Defense World
Omeros' (OMER) Hold Rating Reaffirmed at Needham & Company LLC - MarketBeat
BNP Paribas Financial Markets Buys 7,016 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Reaches New 12-Month HighStill a Buy? - MarketBeat
Stock Of The Day / 12.19.24 / OMER for NASDAQ:OMER by AlexX31 - TradingView
Top Midday Gainers - Marketscreener.com
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges - Benzinga
Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat
Omeros Stock Gains 52% On Successful Trial Results - MarketWatch
Omeros antibody improves overall survival by 68% in rare condition, new analysis finds - Fierce Biotech
Omeros stock soars to 52-week high, hits $12.65 - Investing.com
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges - Yahoo Finance
Omeros stock surges on positive survival data for narsoplimab - Investing.com
Omeros stock jumps after trial outcome (OMER:NASDAQ) - Seeking Alpha
Omeros reports survival benefit with narsoplimab in TA-TMA - Investing.com
Omeros announces narsoplimab trial meets primary endpoint - TipRanks
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA - Business Wire
Omeros (STU:3O8) Operating Income : €-159.24 Mil (TTM As of Sep. 2024) - GuruFocus.com
Omeros (STU:3O8) GF Score : 50/100 (As of Dec. 18, 2024) - GuruFocus.com
Omeros Co. (NASDAQ:OMER) Short Interest Down 16.9% in November - MarketBeat
Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates - Seeking Alpha
Omeros Corporation (OMER) Stock Drops Amid Financial Report Conc - GuruFocus.com
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges - MSN
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting - BioSpace
Omeros reports progress on PNH treatment zaltenibart - Investing.com
Omeros reports progress on PNH treatment zaltenibart By Investing.com - Investing.com UK
Omeros (NASDAQ:OMER) Stock Price Up 7.8%What's Next? - MarketBeat
Omeros stock soars to 52-week high, hits $12.55 By Investing.com - Investing.com Australia
Omeros stock soars to 52-week high, hits $12.55 - Investing.com
Omeros Corporation (OMER) Stock Surges Amidst Biotech Sector Gai - GuruFocus.com
Omeros Corp (OMER) Stock Surges Amid Biotech Sector Activity - GuruFocus.com
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting - The Bakersfield Californian
(OMER) Trading Advice - Stock Traders Daily
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
Omeros (NASDAQ:OMER) Hits New 12-Month HighHere's Why - MarketBeat
Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News - Yahoo Finance
Omeros surges 22% on clarity for BLA resubmission for narsoplimab - MSN
Omeros stock soars to 52-week high, hits $7.53 By Investing.com - Investing.com Australia
Omeros nears resubmission of narsoplimab BLA By Investing.com - Investing.com South Africa
Omeros nears resubmission of narsoplimab BLA - Investing.com India
Omeros stock soars to 52-week high, hits $7.53 - Investing.com
Omeros Corporation Provides Update on Progress Toward BLA Resubmission - Business Wire
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
Omeros (NASDAQ:OMER) Upgraded at StockNews.com - Defense World
Long Term Trading Analysis for (OMER) - Stock Traders Daily
IgA Nephropathy Drugs Market: Driving Rapid Expansion with - openPR
Omeros Corporation (OMER) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):